Navin Fluorine’s growth prospects were initially highlighted with our accumulate call in November 2023 when the stock was trading at ₹3,609 and followed up with a hold call in May 2025 when it was trading at ₹4,242. Our positive stance was based on margin expansion prospects from new projects and capacities the company undertook in the last five years. This has played out as expected. The stock of Navin Fluorine has returned 47 per cent from our May 2025 call. In line with expectations, the valuations have corrected from 47 times one-year forward earnings then to 42 times now. But owing to superior execution across three verticals along with improved operating leverage reflected in expanded margins, the stock has outperformed.

The company is geared to sustain the growth momentum across segments with capacity addition in the next two years. Post the stock’s good run in the last three years, we reiterate our hold call on the stock for investors to benefit from earnings growth in the long run, even as operational impact from energy price volatility is at a heightened level currently.

Segment drivers

Navin Fluorine operates across three segments — Speciality Chemicals (33 per cent of 9MFY26 revenues) manufactures intermediates for APIs across agrochemicals and pharmaceuticals; High Performance Products (HPP) division (51 per cent) manufactures Hydrofluorocarbons (HFCs), which includes client-specific facilities; Contract Development and Manufacturing Outsourcing division or the CDMO (16 per cent) addresses clients in agro and pharma space in developing and manufacturing key and advanced intermediates.

Specality chemicals growth has been driven by fluoro-speciality products for agrochemical clients from a dedicated plant built at a cost of ₹540 crore. The facility that was commercialised in December 2024 has been utilised to only half the extent in the first phase. The company is engaging in initial discussions with clients to utilise the remaining half in the next one year. With strong outlook on orders, it is also debottlenecking its existing multi-purpose plant (MPP), which is expected to generate revenues of ₹140-170 crore at full utilisation that will start from Q3FY27. The company expects to start production of Opteon by Q1FY27. This is a proprietary product of client Chemours, which is used as a cooling fluid in data centres. The $14-million facility was part financed by the client of upto $5 million. The product has high potential and should ramp up production after the initial phase.

TheHPP division has benefited from strong prices and demand for R32 gas used for room air conditioners, both domestically and internationally. The expanded R32 facility also aided the strong growth. The company is further expanding the facility with an investment of ₹237 crore, which should be operational by Q3FY27 and expected to deliver revenues of ₹600-825 crore at full utilisation. It has also commercialised a facility for producing AHF (Anhydrous Hydrogen Fluoride), which is used in R32 production. But the company aims to utilise the output internally, in trade channels and also to explore high value-added applications in electronics grade. This is the advanced material segment Navin Fluorine is exploring with base material (AHF), CDMO operations with clients and its fluorine chemistry expertise.

The CDMO division has an aspirational target of $100 million in revenues and the company is on its way to meeting the target with revenues of ₹360 crore in 9MFY26 or $40 million. The company has commercialised a new cGMP-4 facility along with validation from a European client. This product should have a strong three-year visibility with client molecule expanding in market potential after FDA approval.

Finance and valuation

The company reported an EBITDA margin of 32 per cent in 9MFY26, which is a 930-basis point improvement over FY25. High utilisation of assets (refrigerant gases, speciality chemicals’ fluoro-agchem products, CDMO’s cGMP facilities) allowed for operational leverage to play out, which aided margins. In the next wave: Facility expansion (R32 facility, new cCGMP 4 facility, debottlenecking) and high-value projects (Chemours, advanced materials with AHF) should support the higher EBITDA margins and continue the operating leverage from sustained revenue growth. With a very comfortable net debt to equity of 0.03 times as of December 2025, the company balance sheet is supportive of further expansion.

While company factors of high growth and margin expansion are positive, the risk is from macro-environmental factors. Risk stems from energy price volatility, which can hamper normal functioning of operations or from downstream demand from CDMO, data centres, agro-chemical sectors — which is only recently recovering from over stocking post Russia-Ukraine conflict.

Navin Fluorine is trading at 42 times one-year forward earnings, which is a discount to its past five-year average of 47 times but is still a premium valuation. This stems from higher value-added operations in fluorination, CDMO segment and strong client engagement. With growth, risk and valuations on an even keel, we recommend investors with a three-five-year perspective and willingness hold the stock for long-term earnings growth.

Published on March 21, 2026